Printer Friendly

Chemotherapy Induced Nausea and Vomiting Pipeline Review Report H2 2015.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

NEW YORK, Oct. 7, 2015 /PRNewswire-iReach/ --ACCESS REPORT @ Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015

Summary

'Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015', provides an overview of the Chemotherapy Induced Nausea and Vomiting's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

AVAIL SAMPLE @ Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015

SCOPE

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chemotherapy Induced Nausea and Vomiting and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chemotherapy Induced Nausea and Vomiting products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chemotherapy Induced Nausea and Vomiting pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products

KEYPOINTS

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

LEAVE YOUR QUERIES @ Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015

Media Contact: Norah Trent, WiseGuy Reports, +1 646 845 9349, sales@wiseguyreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE WiseGuy Reports
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 7, 2015
Words:801
Previous Article:Robbins Arroyo LLP: Globus Medical, Inc. (GMED) Misled Shareholders According to a Recently Filed Class Action.
Next Article:Epstein-Barr Viral Infections Pipeline Review Report H2 2015.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters